Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Embecta Corp. filings document a Nasdaq-listed medical device and medical supplies company with common stock trading under EMBC. Its regulatory disclosures cover operating and financial results, capital-structure information, material-event reports, and governance matters tied to its board, annual meeting and executive-compensation votes.
Recent 8-K reports furnish quarterly and annual results and disclose director changes, board leadership roles and stockholder voting outcomes. Proxy materials describe annual meeting proposals, director elections, auditor ratification, compensation votes, and business context for Embecta's insulin injection franchise, restructuring actions, discontinued patch pump program, and broader medical supplies strategy.
Embecta Corp. furnished a press release announcing results for the quarter ended June 30, 2025. The company submitted an 8-K to share this update and included the full press release as Exhibit 99.1. The filing notes the update relates to results of operations and financial condition. Shares trade on Nasdaq under EMBC.